{
    "2019-12-18": [
        [
            {
                "time": "",
                "original_text": "高溢价“卖身”失败 佐力药业靠补助盈利能走多远？ 并购重组异常",
                "features": {
                    "keywords": [
                        "高溢价",
                        "卖身失败",
                        "佐力药业",
                        "补助盈利",
                        "并购重组异常"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "电鳗快报|业绩持续四年下滑 佐力药业3600万元补助或迎转机 盈利能力下降",
                "features": {
                    "keywords": [
                        "业绩下滑",
                        "佐力药业",
                        "补助",
                        "转机",
                        "盈利能力下降"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "2019十大最受机构关注个股 海康威视位列首位",
                "features": {
                    "keywords": [
                        "2019",
                        "机构关注",
                        "海康威视",
                        "首位"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "【民生医药|公司深度】复星医药：整合能力提升+创新增量催化，业绩迎来兑现期",
                "features": {
                    "keywords": [
                        "复星医药",
                        "整合能力提升",
                        "创新增量",
                        "业绩兑现期"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}